<DOC>
	<DOCNO>NCT00185796</DOCNO>
	<brief_summary>To evaluate feasibility safety TLI/ATG conditioning allogeneic HCT elderly patient advance stage MDS MPD .</brief_summary>
	<brief_title>TLI &amp; ATG Non-Myeloablative Allogeneic Transplantation MDS MPD</brief_title>
	<detailed_description>Total Lymphoid Irradiation Anti-Thymocyte Globulin Conditioning Non-Myeloablative Allogeneic Hematopoietic Cell Transplantation Treatment Myelodysplastic Syndromes Myeloproliferative Disorders ( except CML ) . To evaluate feasibility safety TLI/ATG conditioning allogeneic HCT elderly patient co-morbid condition preclude myeloablative transplantation advance stage MDS MPD .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Myeloproliferative Disorders</mesh_term>
	<mesh_term>Hematologic Neoplasms</mesh_term>
	<mesh_term>Antilymphocyte Serum</mesh_term>
	<criteria>GENERAL INCLUSION CRITERIA General inclusion criterion must include least one following : Patients age &gt; 49 &lt; 75 year MDS MPD Patients age &lt; 49 year high risk regimen relate toxicity use standard high dose regimen . Factors consider high risk include preexist condition chronic disease affect kidney , liver , lung , heart . Patients secondary MDS follow prior autologous transplant . An HLAidentical related HLAmatched unrelated donor available . ABO incompatibility acceptable . A sign informed consent form . MYELODYSPLASTIC SYNDROME CRITERIA Diagnosis MDS classifiable FAB system refractory anemia ( RA ) , refractory anemia ring sideroblast ( RARS ) , chronic myelomonocytic leukemia ( CMML ) , refractory anemia excess blast ( RAEB ) , MDS transform acute leukemia . Patients advanced MDS must cytoreduced &lt; 10 % marrow blast prior receive condition TLI/ATG . Less 10 % marrow blast must document marrow examination within 1 month start conditioning . The cytoreductive regimen determine refer center . Patients evolution AML require complete remission define blast count le 5 % marrow aspirate adequate cellularity . Presence residual dysplastic feature follow cytoreductive therapy acceptable . All patient high risk disease , example `` intermediate2 '' `` high risk '' disease IPSS score . Other select patient low IPSS score may consider discussion BMT attend physician , group , PI study . MYELOPROLIFERATIVE DISORDERS Myeloproliferative disorder include : Philadelphia chromosomenegative CML . Patients polycythemia vera persistent thrombotic hemorrhagic complication despite conventional therapy , progress postpolycythemic marrow fibrosis . Patients essential thrombocythemia persistent thrombotic hemorrhagic complication despite conventional therapy , progress myelofibrosis . Patients agnogenic myeloid metaplasia high risk disease , example `` intermediate '' `` high risk '' accord Lille Scoring System . Patients must cytoreduced &lt; 10 % marrow blast . Less 10 % marrow blast must document marrow examination within 1 month initiation TLI/ATG . The cytoreductive regimen determine refer center . Patients evolution AML require complete remission define blast count le 5 % marrow aspirate adequate cellularity . Presence residual dysplastic feature follow cytoreductive therapy acceptable . INCLUSION CRITERIA RELATED DONORS Related patient genotypically phenotypically HLAidentical . Donor age &lt; 75 unless clear P.I Capable give write , informed consent . Donor must consent PBSC mobilization GCSF apheresis INCLUSION CRITERIA UNRELATED DONORS Donors must HLAmatched define follow criterion : Matched HLADRB1 DQB1 high resolution type . Serologic match recognize HLAA , HLAB , HLAC antigens , molecular match least 5 6 HLAA , HLAB , HLAC antigens high resolution type . Donor must consent PBSC mobilization GCSF apheresis . Bone marrow unrelated donor eligible protocol . GENERAL EXCLUSION CRITERIA Organ dysfunction define follow : Renal : Patients normal creatinine eligible study without need 24 hr urine collection creatinine clearance . Patients elevate creatinine require 24 hr urine collection . If creatinine clearance &lt; 50 ml/min patient determine inclusion case case basis . Cardiac : Ejection fraction &lt; 40 % , symptomatic congestive heart failure require therapy , poorly control cardiac arrythmias , poorly control hypertension inability maintain steadystate blood pressure 150/90 . Pulmonary : Requirement supplemental oxygen administration , pulmonary function test showing ( 1 ) DLCO &lt; 50 % predict , ( 2 ) TLC &lt; 30 % , ( 3 ) FEV1 &lt; 30 % . Hepatic : Patients clinical laboratory evidence liver disease would evaluate cause liver disease , clinical severity term liver function degree portal hypertension . Patients exclude find fulminant liver failure , cirrhosis liver evidence portal hypertension , alcoholic hepatitis , esophageal varix , history bleed esophageal varix , hepatic encephalopathy , uncorrectable hepatic synthetic dysfunction evidence prolongation prothrombin time , ascites related portal hypertension , bacterial fungal liver abscess . Biliary obstruction , chronic viral hepatitis total serum bilirubin &gt; 3 mg/dl , symptomatic biliary disease . Bone marrow document blast count &gt; =10 % . Presence active nonhematologic malignancy ( except localize nonmelanoma skin malignancy ) hematologic malignancy MDS MPD list inclusion criterion . Active CNS involvement disease . Karnofsky performance score &lt; = 60 % LanskyPlay Performance score &lt; 50 pediatric patient . Life expectancy severely limited disease malignancy . Fungal infection radiological progression despite amphotericin product active triazole &gt; 1 month . Active bacterial infection . Patients fertile age refuse contraception twelve month period posttransplant . Pregnant lactating female . HIV seropositivity . Severe psychological illness . EXCLUSION CRITERIA RELATED DONORS Identical twin Any contraindication administration subcutaneous GCSF dose 16mg/kg/d five consecutive day Serious medical psychological illness Pregnant lactating female Prior malignancy within precede five year , exception nonmelanoma skin cancer . HIV seropositivity</criteria>
	<gender>All</gender>
	<minimum_age>49 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2015</verification_date>
</DOC>